*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
The peptide used to generate this antibody is available for purchase (GTX22248-PEP).
Tris saline pH7.3, 0.02% sodium azide, 0.5% BSA.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.50 mg/ml (Please refer to the vial label for the specific concentration.)
Peptide with sequence GKCRQLSRLCRNHCR, from the C Terminus of the protein sequence according to NP_054883.3; NP_659003.1; NP_001158077.1.
Purified by ammonium sulphate precipitation followed by antigen affinity chromatography
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
FXYD domain containing ion transport regulator 5 , DYSAD , HSPC113 , IWU1 , KCT1 , OIT2 , PRO6241 , RIC
This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, is a glycoprotein that functions in the up-regulation of chemokine production, and it is involved in the reduction of cell adhesion via its ability to down-regulate E-cadherin. It also promotes metastasis, and has been linked to a variety of cancers. Alternative splicing results in multiple transcript variants. [RefSeq curation by Kathleen J. Sweadner, Ph.D., email@example.com., Sep 2009]